Peptide Bioavailability by Route of Administration

Bioavailability is the fraction of an administered drug dose that reaches systemic circulation in active form. For peptides, this varies enormously by route — from near-100% (IV) to near-zero (most topical applications). Understanding this determines whether a peptide can work as intended or whether it is destroyed before reaching its target.

Why peptide bioavailability is uniquely challenging

Peptides are vulnerable to two biological barriers that small-molecule drugs largely avoid:

1. Enzymatic degradation. Proteases in the GI tract, blood, skin, and nasal mucosa rapidly cleave peptide bonds. A typical unmodified peptide has a circulating half-life of minutes.
2. Poor membrane permeability. Peptides are large (typically 500–5000 Da), hydrophilic, and often charged — properties that prevent passive diffusion across epithelial barriers and the blood-brain barrier.

These twin barriers explain why most therapeutic peptides require injection and why oral peptide delivery has been one of pharmacology's longest-standing challenges.

Bioavailability by route

Intravenous (IV)

Bioavailability: 100% by definition. The peptide enters the bloodstream directly. The limitation is rapid enzymatic clearance — many peptides have circulating half-lives of 2–15 minutes IV. Used clinically for peptides requiring precise dosing (e.g., oxytocin for labor induction, vasopressin for diabetes insipidus).

Subcutaneous (SC)

Bioavailability: 50–80% for most peptides. Absorption from the subcutaneous depot is slower than IV, creating a sustained release effect. Some enzymatic degradation occurs at the injection site. This is the workhorse route for therapeutic peptides: semaglutide, growth hormone, insulin, and most research peptides are administered SC.

Absorption rate depends on injection site blood flow: abdomen > thigh > upper arm > buttock.

Intramuscular (IM)

Bioavailability: 60–90%. Faster absorption than SC due to higher muscle blood flow. Used when faster onset is needed or when depot formation in muscle is therapeutically useful.

Intranasal

Bioavailability: 1–30%, highly variable. The nasal epithelium provides direct access to systemic circulation (avoiding first-pass hepatic metabolism) and partial access to the CNS via olfactory pathways. Absorption is limited by the small surface area, mucociliary clearance, and enzymatic activity in nasal mucosa.

Examples: Semax and Selank are administered intranasally with clinically meaningful brain concentrations. Oxytocin nasal spray shows behavioral effects at doses suggesting ~10% systemic bioavailability. Nasal semaglutide (under development) uses absorption enhancers.

Oral

Bioavailability: <1% for most unmodified peptides. The GI tract is an extremely hostile environment: stomach acid (pH 1–3), pepsin, pancreatic proteases, and brush-border peptidases destroy most peptides before absorption.

Notable exceptions: BPC-157 shows apparent oral activity in rodent models — unusual for a peptide and attributed to gastric stability from its gastric-juice origin. Oral semaglutide (Rybelsus) uses the SNAC absorption enhancer to achieve ~1% bioavailability — sufficient because semaglutide is potent at nanomolar concentrations. Cyclosporine, a cyclic peptide, achieves ~30% oral bioavailability due to its cyclic structure and lipophilicity.

Topical (dermal)

Bioavailability: Near zero for systemic effects. The stratum corneum is an effective barrier against molecules above ~500 Da. Peptides cannot cross intact skin in therapeutically meaningful quantities for systemic effects.

Local dermal effects are a different story. Peptides like GHK-Cu, Matrixyl (Pal-GHK), and Argireline can act on fibroblasts and keratinocytes in the upper dermis without needing systemic absorption. Their "bioavailability" in the dermal target zone — not the bloodstream — is sufficient for cosmetic effects.

Engineering improved bioavailability

Several strategies extend peptide survival and absorption:

• PEGylation: Attaching polyethylene glycol chains shields peptides from enzymatic degradation and renal clearance. PEG-MGF is a classic example.
• Lipidation: Attaching fatty acid chains (as in semaglutide's C-18 chain or liraglutide's C-16 chain) enables albumin binding, extending half-life from minutes to days/weeks.
• Cyclization: Circular peptides resist exopeptidases. Cyclosporine's oral bioavailability is partly due to its cyclic structure.
• D-amino acid substitution: Replacing L-amino acids with D-enantiomers at protease-sensitive positions prevents cleavage while maintaining receptor binding.
• Absorption enhancers: SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) enables oral semaglutide by transiently increasing gastric epithelial permeability.

Practical implications

When evaluating a peptide product, ask three questions about bioavailability:

1. What route is specified? If a peptide is designed for injection but sold as an oral supplement, the bioavailability is likely negligible.
2. Has the peptide been modified for the intended route? Lipidated, PEGylated, or cyclized peptides may have meaningful oral or nasal bioavailability. Unmodified linear peptides generally do not.
3. Is local or systemic effect the goal? Topical peptides for skin effects are valid — topical peptides for systemic effects are not.